CONDITION

Hepatic Lipidosis in Cats

Why this matters now

Hepatic lipidosis is the most common acquired liver disease in cats and represents a unique metabolic vulnerability of the feline species. Unlike dogs and humans, cats have limited metabolic pathways for processing large quantities of mobilised body fat, making them susceptible to hepatic fat accumulation when caloric intake drops significantly. The condition most commonly develops in overweight or obese cats that stop eating or dramatically reduce food intake for three or more consecutive days. The triggering event for the anorexia may be anything from illness, stress, dietary change, household disruption, or even temporary inaccessibility of food. Indoor-only cats with excess body weight represent the highest-risk population, and the increasing prevalence of feline obesity has made hepatic lipidosis an increasingly recognised clinical entity.

Once triggered, hepatic lipidosis follows a relatively predictable metabolic cascade. As the cat stops eating, the body mobilises stored fat from adipose tissue to provide energy. This fat is transported to the liver for processing, but the feline liver's limited capacity to metabolise and export large quantities of triglycerides means the fat accumulates within hepatocytes faster than it can be processed. As fat fills the liver cells, it disrupts normal hepatocyte function, impairing the liver's ability to produce proteins, process bilirubin, synthesise clotting factors, and detoxify metabolic waste products. The resulting liver dysfunction produces nausea and malaise that further suppress appetite, creating a vicious cycle where the worsening liver disease perpetuates the very anorexia that caused it. Without intervention to break this cycle, the condition progresses to liver failure. However, with aggressive nutritional support — typically through a feeding tube — the liver can regenerate and recover in the majority of cases, making this one of the few serious liver conditions where the prognosis, with appropriate management, is often favourable.

Signals & patterns

Early signals

Progressive appetite decline

The most critical early sign is a significant reduction or cessation of food intake, particularly in an overweight cat. The appetite loss may begin as pickiness or reduced portion sizes before progressing to complete food refusal over several days.

Withdrawal and reduced activity

The cat may become quieter, seek out hiding places, and show less interest in interaction or play. This behavioural change may precede other visible signs and can easily be misinterpreted as the cat simply sleeping more.

Rapid weight loss

Noticeable weight loss occurring over days to weeks in a previously overweight cat, often most apparent as prominence of the spine, hip bones, and shoulder blades. The speed of weight loss may be striking in severely affected cats.

Intermittent vomiting or nausea

Nausea-related behaviours such as lip-licking, drooling, or occasional vomiting may develop as liver function begins to decline. The cat may approach food with apparent interest but then turn away, suggesting nausea rather than simple disinterest.

Later signals

Jaundice (icterus)

Yellowing of the whites of the eyes, the inner ear flaps, the gums, and the skin becomes visible as bilirubin accumulates in the blood due to impaired hepatic processing. Jaundice is often the sign that prompts veterinary attention and indicates significant hepatic compromise.

Marked muscle wasting

Progressive loss of muscle mass, particularly over the head, spine, and hindquarters, becomes apparent as the body catabolises protein stores alongside fat mobilisation. The cat may appear dramatically thinner than it did just weeks earlier.

Hepatic encephalopathy signs

In severe cases, impaired liver detoxification allows ammonia and other neurotoxins to accumulate in the blood, producing neurological signs including disorientation, aimless wandering, head pressing, drooling, and altered mentation. These signs indicate advanced liver failure.

Coagulopathy

Impaired hepatic synthesis of clotting factors may produce signs of abnormal bleeding, including bruising, prolonged bleeding from minor wounds, or blood in the stool or vomit. This reflects severe compromise of the liver's protein-synthesising capacity.

Click to read about the biological mechanisms

How this is usually investigated

Investigation of suspected hepatic lipidosis typically involves a combination of blood work, imaging, and liver sampling to confirm the diagnosis and assess the severity of hepatic compromise.

Blood biochemistry panel

Purpose: To evaluate liver enzyme levels (ALT, AST, ALP, GGT), bilirubin concentration, albumin, blood glucose, cholesterol, and electrolytes. Hepatic lipidosis typically produces markedly elevated ALP with more modest increases in ALT and AST, alongside hyperbilirubinaemia and sometimes hypoglycaemia.
Considerations: The pattern of enzyme elevation can help distinguish hepatic lipidosis from other liver diseases. Very high ALP with relatively lower ALT/AST is characteristic, though overlap with other hepatobiliary conditions exists. Electrolyte abnormalities, particularly hypokalaemia and hypophosphataemia, are common and clinically important to identify.

Coagulation profile

Purpose: To assess the liver's ability to produce clotting factors, as hepatic lipidosis can impair coagulation. This is particularly important before any invasive procedures such as liver biopsy.
Considerations: Prolonged clotting times indicate significant hepatic synthetic compromise and increase the risk of bleeding during procedures. Vitamin K supplementation may be needed before biopsy can be safely performed.

Abdominal ultrasound

Purpose: To evaluate liver size, echogenicity, and parenchymal pattern, and to assess the biliary system and other abdominal organs. A diffusely hyperechoic (bright) liver on ultrasound is characteristic of hepatic lipidosis, reflecting the fatty infiltration of the liver parenchyma.
Considerations: Ultrasound findings alone are not pathognomonic, as other diffuse hepatopathies can produce similar appearances. However, ultrasound provides guidance for fine-needle aspirate or biopsy and helps exclude other causes of hepatic disease such as biliary obstruction, hepatic masses, or cholangitis.

Hepatic fine-needle aspirate or biopsy

Purpose: Cytological examination of liver cells obtained by fine-needle aspirate can rapidly confirm the diagnosis by demonstrating hepatocytes distended with fat vacuoles. This is often considered the definitive diagnostic procedure for hepatic lipidosis.
Considerations: Fine-needle aspirate is less invasive than wedge biopsy and can often be performed with ultrasound guidance under sedation. However, coagulation status should be assessed first, as the fatty liver may bleed more than normal. Cytology can confirm fat accumulation but may not fully characterise concurrent conditions such as cholangitis that may require histopathological assessment.

Assessment for underlying triggers

Purpose: To identify any primary condition that triggered the initial anorexia, as hepatic lipidosis frequently develops secondary to another illness. Investigation may include assessment for pancreatitis, inflammatory bowel disease, cholangitis, diabetes, neoplasia, or other conditions that could have caused the initial decline in food intake.
Considerations: Identifying and treating any underlying trigger is important for long-term management, as the cat may relapse if the primary cause of anorexia is not addressed alongside the hepatic lipidosis itself. Up to 95% of cats with hepatic lipidosis have an identifiable underlying condition.

Options & trade-offs

The cornerstone of hepatic lipidosis management is nutritional support, which must be sustained long enough for the liver to regenerate and resume normal function. The approach focuses on providing adequate calories and nutrients to reverse the metabolic crisis driving fat accumulation.

Feeding tube placement

Placement of a feeding tube — most commonly an oesophagostomy tube or nasogastric tube — allows controlled delivery of a complete liquid diet directly into the gastrointestinal tract, bypassing the cat's anorexia. This is the single most important intervention and is considered the standard of care for managing hepatic lipidosis.

Trade-offs: Oesophagostomy tubes require a brief anaesthetic for placement but can remain in place for weeks to months and allow blended commercial diets to be delivered. Nasogastric tubes can be placed without anaesthesia but are limited to liquid diets and are less comfortable for long-term use. Feeding tubes require owner commitment to regular feeding schedules and tube maintenance but provide the most reliable route for nutritional rehabilitation.

Gradual caloric reintroduction

Feeding is introduced gradually to avoid refeeding syndrome, starting at approximately 25-30% of the cat's resting energy requirements and increasing over three to five days to full caloric intake. The diet is typically high in protein to support hepatic regeneration and address the protein deficiency that contributed to the condition.

Trade-offs: Too-rapid reintroduction of calories can precipitate refeeding syndrome, a potentially dangerous metabolic disturbance characterised by severe hypophosphataemia, hypokalaemia, and hypomagnesaemia. Careful monitoring of electrolytes during the initial refeeding period is essential.

Fluid therapy and electrolyte correction

Intravenous or subcutaneous fluid therapy addresses dehydration and provides a route for electrolyte supplementation. Potassium, phosphorus, and B-vitamin supplementation are commonly required, as these become depleted during the fasting period and can drop further during refeeding.

Trade-offs: Fluid therapy addresses immediate dehydration and electrolyte imbalances but must be carefully balanced, as overhydration in a cat with compromised hepatic albumin production can contribute to fluid accumulation. Regular monitoring of electrolytes guides supplementation.

Anti-nausea medication

Antiemetic medications such as maropitant or ondansetron can help control the nausea that perpetuates the anorexia cycle. Reducing nausea may also improve the cat's tolerance of tube feeding and potentially encourage voluntary food intake as recovery progresses.

Trade-offs: Anti-nausea medications address a key component of the self-perpetuating cycle but do not treat the underlying hepatic pathology. They are most effective as part of a comprehensive management plan that includes nutritional support.

Treatment of underlying condition

Identifying and treating any primary condition that triggered the initial anorexia is essential for preventing relapse. This may include management of pancreatitis, inflammatory bowel disease, diabetes, or other concurrent conditions.

Trade-offs: Addressing the underlying trigger is crucial for long-term success but may require its own diagnostic workup and treatment plan, adding complexity to the overall management. Some underlying conditions may be challenging to diagnose while the cat is acutely unwell with hepatic lipidosis.

Common misconceptions

Misconception:

"Hepatic lipidosis only affects very fat cats."

Reality:

While overweight and obese cats are at highest risk because they have larger fat stores available for mobilisation, hepatic lipidosis can develop in cats of normal body weight that undergo significant caloric restriction. Any cat that stops eating adequately for several days is at some degree of risk, though the risk increases substantially with greater body fat stores. Even moderately overweight cats can develop the condition.

Misconception:

"A cat that stops eating for a day or two will develop hepatic lipidosis."

Reality:

While cats are more vulnerable to the metabolic consequences of fasting than dogs or humans, hepatic lipidosis typically requires several days to a week or more of significantly reduced caloric intake to develop. A day or two of reduced appetite in an otherwise healthy cat, while worth monitoring, does not usually trigger the condition. The risk increases with the duration and severity of the caloric deficit and with the degree of pre-existing obesity.

Misconception:

"Hepatic lipidosis is always fatal."

Reality:

With appropriate and timely nutritional support, the survival rate for hepatic lipidosis is approximately 60-80%. The feline liver has remarkable regenerative capacity, and once adequate nutrition is provided consistently through a feeding tube, the hepatocytes can gradually clear the accumulated fat and resume normal function. Recovery typically takes four to eight weeks of nutritional support. The prognosis worsens with delayed treatment, severe hepatic encephalopathy, or when a serious underlying condition triggered the initial anorexia.

For cat owners, the most important awareness is that significant appetite reduction in an overweight cat represents a situation that warrants attention, particularly if it persists beyond two to three days. Understanding that cats have a unique metabolic vulnerability to fasting — unlike dogs, who can typically tolerate periods of reduced intake more safely — helps frame appropriate concern. Monitoring food intake carefully, especially during stressful periods, illness, or after dietary changes, allows early recognition of a problem. If a cat stops eating, focusing on tempting it with highly palatable, strongly aromatic foods, warming the food slightly, and minimising environmental stressors may help restart voluntary intake before the metabolic cascade of hepatic lipidosis becomes established.

Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS